Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
The relationship between the pretherapy cell cycle characteristics of leukaemic marrow cells and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia was studied in newly diagnosed and relapsed patients who were then treated with either combination chemotherapy consisting of cytosine arabinoside/anthracycline antibiotic +/- 6 thioguanine or with single agent high-dose cytosine arabinoside therapy. The outcome of high-dose cytosine arabinoside therapy was highly dependent upon the per cent of pretherapy cells in S phase with no remissions occurring in patients in whom the 3H-TdR labelling index was less than 6%. In contrast, the outcome of cytosine arabinoside/anthracycline antibiotic therapy was independent of the pretherapy cell cycle characteristics of the leukaemic cells.
D000208:Acute Disease; D000903:Antibiotics, Antineoplastic; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007399:Interphase; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage; D013866:Thioguanine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D003561:Cytarabine; D013866:Thioguanine